BusinessUPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic CancerBy Nasdaq OMXMar 1, 2018, 6:45 PM UTC
BusinessFibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic CancerBy Nasdaq OMXMar 1, 2018, 12:03 PM UTC
BusinessTempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer PatientsBy Nasdaq OMXJan 25, 2018, 3:30 PM UTC
BusinessRafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic CancerBy Nasdaq OMXNov 16, 2017, 2:24 PM UTC
BusinessRafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual MeetingBy Nasdaq OMXSep 8, 2017, 11:00 AM UTC
BusinessTempus and University of California Davis Comprehensive Cancer Center Announce Personalized Medicine Partnership for Cancer PatientsBy Nasdaq OMXAug 31, 2017, 2:00 PM UTC
BusinessHemispherx Updates Status of Immuno-Oncology Program in Pancreatic CancerBy Nasdaq OMXJul 10, 2017, 12:30 PM UTC
BusinessTempus and University of Chicago Medicine Collaborate on Pancreatic Cancer Research ProjectBy Nasdaq OMXJun 22, 2017, 2:30 PM UTC
